Melphalan Hikma

Melphalan, the active ingredient in Melphalan Hikma, is an alkylating agent presented as a intravenous formulation for intravenous use. It treats multiple myeloma, ovarian cancer and malignant melanoma in adult patients.

GNH USA supplies Melphalan Hikma as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide.

Melphalan is an alkylating antineoplastic agent used in the treatment of several solid tumours and hematologic malignancies.

Multiple myeloma: reduces malignant plasma‑cell proliferation and improves survival. Ovarian cancer: incorporated into combination regimens to achieve tumour reduction. Malignant melanoma: employed in advanced disease to inhibit tumour growth.

Adverse reactions may vary in frequency and severity.

Common Side Effects: - Nausea and vomiting - Myelosuppression (neutropenia, anemia, thrombocytopenia) - Alopecia (hair loss) - Fatigue

Serious or Rare Side Effects: - Secondary malignancies (e.g., leukemia) - Severe infections due to immunosuppression - Pulmonary toxicity (interstitial pneumonitis) - Renal toxicity or hemorrhagic cystitis - Cardiac toxicity (arrhythmias) - Severe mucositis

Careful monitoring and patient assessment are essential when using melphalan.

Monitor blood counts: perform regular complete blood count tests to detect myelosuppression. Assess renal function: evaluate serum creatinine and adjust therapy if impairment is present. Evaluate hepatic function: check liver enzymes before and during treatment. Avoid in patients with known hypersensitivity to alkylating agents. Use effective contraception: both male and female patients should employ reliable birth control during therapy and for a defined period after. Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Melphalan may interact with other medicines, altering efficacy or toxicity.

Major Interactions (Avoid): - Concurrent use with other myelosuppressive agents (e.g., cyclophosphamide) may exacerbate bone‑marrow suppression. - Live vaccines: immunosuppression can reduce vaccine effectiveness and increase infection risk.

Moderate Interactions (Monitor Closely): - Nephrotoxic drugs (e.g., cisplatin) may increase renal toxicity. - Anticoagulants (e.g., warfarin) may heighten bleeding risk. - CYP450 inducers or inhibitors (e.g., rifampin, azole antifungals) may affect melphalan metabolism and require dose adjustments.